Apply to trial NCT06574698

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening